A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer
BackgroundColorectal cancer (CRC) ranks among the most prevalent malignancies of the gastrointestinal tract and remains a leading cause of cancer-related mortality worldwide. Although telomere biology has been increasingly implicated in immune modulation and tumor progression, its clinical significa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-05-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2025.1615533/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850255653758566400 |
|---|---|
| author | Yinmeng Zhang Jiawei Fan Jiahui Zhao He Zhu Yan Xia Hong Xu |
| author_facet | Yinmeng Zhang Jiawei Fan Jiahui Zhao He Zhu Yan Xia Hong Xu |
| author_sort | Yinmeng Zhang |
| collection | DOAJ |
| description | BackgroundColorectal cancer (CRC) ranks among the most prevalent malignancies of the gastrointestinal tract and remains a leading cause of cancer-related mortality worldwide. Although telomere biology has been increasingly implicated in immune modulation and tumor progression, its clinical significance in CRC remains poorly understood.MethodsWe developed a telomere score, termed TELscore, by integrating transcriptomic and intratumoral microbiome profiles from publicly available colorectal cancer (CRC) cohorts. To comprehensively characterize TELscore subgroups, we performed pathway enrichment analysis, tumor immune microenvironment (TIME) profiling, and microbiome niche assessment. Whole-slide histopathological images (WSIs) and immunohistochemical (IHC) staining were utilized to visualize immune features, including tertiary lymphoid structures (TLSs), across subgroups. Patients were stratified into high and low TELscore categories, and the predictive robustness was validated across multiple independent training and validation cohorts. Chemotherapeutic drug sensitivity was evaluated using pharmacogenomic data from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Furthermore, the predictive capacity of TELscore for immunotherapy response was independently assessed in an external cohort. Finally, single-cell RNA sequencing (scRNA-seq) analysis was conducted to further dissect the cellular landscape and immunological heterogeneity within the TME.ResultsTELscore stratified patients into two biologically and clinically distinct subgroups. The high TELscore group, which exhibited significantly shorter DFS, showed marked enrichment of tumorigenic pathways such as EMT, along with a distinctly immunosuppressive TME. This was reflected by elevated ESTIMATE/TIDE scores and corroborated by CIBERSORT, which revealed increased infiltration of M0 macrophages and upregulation of immunosuppressive signatures. In contrast, the low TELscore group was enriched for cell cycle related pathways, including E2F targets and the G2/M checkpoint, and demonstrated higher infiltration of pro-inflammatory M1 macrophages. 16S rRNA sequencing further revealed a divergent intratumoral microbiome between subgroups, the high TELscore group harbored significantly greater relative abundance of Selenomonas and Lachnoclostridium, two pathogenic genera previously associated with colorectal tumorigenesis. Complementary histopathological assessment via WSI demonstrated a marked absence of intraTLSs in high TELscore tumors. From a therapeutic standpoint, high TELscore tumors exhibited reduced sensitivity to standard chemotherapeutic agents—including Fluorouracil, Irinotecan, Oxaliplatin, and Docetaxel—as reflected by elevated IC50 values. Conversely, these tumors demonstrated increased susceptibility to MAPK pathway inhibitors, such as Selumetinib and Trametinib. Notably, TELscore also served as a robust predictor of immunotherapy response, which was validated in the IMvigor210 cohort. Finally, scRNA analysis highlighted profound cellular and functional divergence between TELscore subgroups. We identified intensified intercellular communication between inflammatory macrophages and fibroblasts, reinforcing the presence of an immunosuppressive niche.ConclusionTELscore is a robust stratification tool that captures the interplay between tumor biology, immune characteristics, and microbial ecology in colorectal cancer. By identifying clinically relevant subtypes with distinct therapeutic vulnerabilities, TELscore offers a powerful framework to advance personalized treatment and precision oncology. |
| format | Article |
| id | doaj-art-df2462d67baa48ebbab896eb54e4988b |
| institution | OA Journals |
| issn | 2296-889X |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj-art-df2462d67baa48ebbab896eb54e4988b2025-08-20T01:56:49ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2025-05-011210.3389/fmolb.2025.16155331615533A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancerYinmeng ZhangJiawei FanJiahui ZhaoHe ZhuYan XiaHong XuBackgroundColorectal cancer (CRC) ranks among the most prevalent malignancies of the gastrointestinal tract and remains a leading cause of cancer-related mortality worldwide. Although telomere biology has been increasingly implicated in immune modulation and tumor progression, its clinical significance in CRC remains poorly understood.MethodsWe developed a telomere score, termed TELscore, by integrating transcriptomic and intratumoral microbiome profiles from publicly available colorectal cancer (CRC) cohorts. To comprehensively characterize TELscore subgroups, we performed pathway enrichment analysis, tumor immune microenvironment (TIME) profiling, and microbiome niche assessment. Whole-slide histopathological images (WSIs) and immunohistochemical (IHC) staining were utilized to visualize immune features, including tertiary lymphoid structures (TLSs), across subgroups. Patients were stratified into high and low TELscore categories, and the predictive robustness was validated across multiple independent training and validation cohorts. Chemotherapeutic drug sensitivity was evaluated using pharmacogenomic data from the Genomics of Drug Sensitivity in Cancer (GDSC) database. Furthermore, the predictive capacity of TELscore for immunotherapy response was independently assessed in an external cohort. Finally, single-cell RNA sequencing (scRNA-seq) analysis was conducted to further dissect the cellular landscape and immunological heterogeneity within the TME.ResultsTELscore stratified patients into two biologically and clinically distinct subgroups. The high TELscore group, which exhibited significantly shorter DFS, showed marked enrichment of tumorigenic pathways such as EMT, along with a distinctly immunosuppressive TME. This was reflected by elevated ESTIMATE/TIDE scores and corroborated by CIBERSORT, which revealed increased infiltration of M0 macrophages and upregulation of immunosuppressive signatures. In contrast, the low TELscore group was enriched for cell cycle related pathways, including E2F targets and the G2/M checkpoint, and demonstrated higher infiltration of pro-inflammatory M1 macrophages. 16S rRNA sequencing further revealed a divergent intratumoral microbiome between subgroups, the high TELscore group harbored significantly greater relative abundance of Selenomonas and Lachnoclostridium, two pathogenic genera previously associated with colorectal tumorigenesis. Complementary histopathological assessment via WSI demonstrated a marked absence of intraTLSs in high TELscore tumors. From a therapeutic standpoint, high TELscore tumors exhibited reduced sensitivity to standard chemotherapeutic agents—including Fluorouracil, Irinotecan, Oxaliplatin, and Docetaxel—as reflected by elevated IC50 values. Conversely, these tumors demonstrated increased susceptibility to MAPK pathway inhibitors, such as Selumetinib and Trametinib. Notably, TELscore also served as a robust predictor of immunotherapy response, which was validated in the IMvigor210 cohort. Finally, scRNA analysis highlighted profound cellular and functional divergence between TELscore subgroups. We identified intensified intercellular communication between inflammatory macrophages and fibroblasts, reinforcing the presence of an immunosuppressive niche.ConclusionTELscore is a robust stratification tool that captures the interplay between tumor biology, immune characteristics, and microbial ecology in colorectal cancer. By identifying clinically relevant subtypes with distinct therapeutic vulnerabilities, TELscore offers a powerful framework to advance personalized treatment and precision oncology.https://www.frontiersin.org/articles/10.3389/fmolb.2025.1615533/fullcolorectal cancertelomeremicrobiometumor microenvironmentprognosis |
| spellingShingle | Yinmeng Zhang Jiawei Fan Jiahui Zhao He Zhu Yan Xia Hong Xu A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer Frontiers in Molecular Biosciences colorectal cancer telomere microbiome tumor microenvironment prognosis |
| title | A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer |
| title_full | A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer |
| title_fullStr | A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer |
| title_full_unstemmed | A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer |
| title_short | A telomere-associated molecular landscape reveals immunological, microbial, and therapeutic heterogeneity in colorectal cancer |
| title_sort | telomere associated molecular landscape reveals immunological microbial and therapeutic heterogeneity in colorectal cancer |
| topic | colorectal cancer telomere microbiome tumor microenvironment prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2025.1615533/full |
| work_keys_str_mv | AT yinmengzhang atelomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT jiaweifan atelomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT jiahuizhao atelomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT hezhu atelomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT yanxia atelomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT hongxu atelomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT yinmengzhang telomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT jiaweifan telomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT jiahuizhao telomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT hezhu telomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT yanxia telomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer AT hongxu telomereassociatedmolecularlandscaperevealsimmunologicalmicrobialandtherapeuticheterogeneityincolorectalcancer |